Novo Nordisk and Gilead team up to test fatty liver disease treatment

Latest Posts

Brazil coronavirus deaths climb to 46,510, cases near 1 million

By Admin

Brazil recorded 1,269 additional COVID-19 deaths on Wednesday, bringing its official death toll from the novel coronavirus to 46,510, the most in the world outside...

Comments closed

Requiring masks ‘political hazard’ as COVID-19 surges in California breadbasket

By Admin

The first wave of COVID-19 came slowly to San Joaquin County in the heart of California's breadbasket, but the much-feared second surge is roaring through,...

Comments closed

Mothers as ‘trauma surgeons:’ the anguish of raising black boys in America

By Admin

Raising black boys in America involves "constant mental anguish," Danielle Pattillo, a special education teacher in New York City and mother to two sons, ages...

Comments closed

Record spike in new coronavirus cases reported in six U.S. states as reopening accelerates

By Admin

New coronavirus infections hit record highs in six U.S. states on Tuesday, marking a rising tide of cases for a second consecutive week as most...

Comments closed

Some Amazon villagers eschew drugs for COVID-19, take ‘toothache plant’ herbal tea

By Admin

Some villagers in the eastern Amazon are spurning Brazilian government advice to take the malaria drug hydroxychloroquine to keep the novel coronavirus at bay and...

Comments closed

The clinical trial will be a study combining Novo Nordisk’s semaglutide drug and Gilead’s cilofexor and firsocostat for treatment of patients with Nonalcoholic steatohepatitis (NASH), Novo Nordisk, best known for its diabetes drugs, said on Friday.

Original source: https://health.economictimes.indiatimes.com/news/pharma/novo-nordisk-and-gilead-team-up-to-test-fatty-liver-disease-treatment/68848436?utm_source=RSS&utm_medium=ETRSS

Also Read: Rajkot : Pharmacists unite against online rivals